HIV and Alcohol Research Center Focused on Polypharmacy (HARP) Pilot 2 (2nd HARP Pilot Intervention)
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age50+
SponsorYale University
About this trial
The focus of this pilot will be on falls and neurocognitive symptoms, and the impact of alcohol, cannabis use, and medications on these outcomes. The rationale is that alcohol use at any level may interact with neurocognitively active medications, alcohol, and cannabis use leading to falls and impaired cognition.
Eligibility criteria
Qualifiers
HIV+
have visited a local VA site in within the past year
had an AUDIT-C indicating current alcohol use
taking 5 or more non-ART medications, including an NCAM (i.e., benzodiazepines, opioids, muscle relaxants, sleeping medication, and selective serotonin reuptake inhibitors)
Disqualifiers
Inpatient individuals
Patients with an Alcohol Use Disorder (AUD) diagnosis in the past 12 months
Patients who test positive on the Alcohol Symptom Checklist for moderate or severe AUD during the screening process
Trial design
Treatments tested in this trial
- Information Motivation Behavioral and Motivational Interviewing (IMB-MI) technique
Treatment groups
100 Participants
are divided into 1 treatment groupSponsors and collaborators
Yale University
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Collaborator
Source ClinicalTrials.gov